Introduction
The outcome for patients with tetralogy of Fallot has dramatically improved since the introduction of surgical repair.
1,2 Pulmonary regurgitation, a common sequela of repair, may be well tolerated for decades; it is known, however, to have long-term detrimental effects, including exercise intolerance, progressive right ventricular (RV) dilatation and dysfunction, ventricular and atrial tachycardia, congestive heart failure and sudden cardiac death. 3, 4 Implantation of a competent pulmonary valve is commonly undertaken to avoid these adverse clinical outcomes.
Cardiopulmonary exercise (CPEX) testing to assess objective exercise tolerance has been proposed as a potential tool for optimal timing of pulmonary valve replacement (PVR), as symptoms are often volunteered late by patients and preceded by impairment in CPEX testing results. Indeed, CPEX testing has recently become part of routine medical surveillance of these patients in our centre. In other disease settings impaired cardiopulmonary exercise performance is associated with a higher perioperative surgical risk, 5, 6 but the association between baseline peak oxygen uptake and surgical risk has not been explored to date in a large cohort of adults with previous repair of tetralogy of Fallot (rTOF) undergoing PVR.
In this study, we therefore examined contemporary outcomes of rTOF patients undergoing surgical PVR in a single, tertiary centre, with particular reference to preoperative baseline CPEX testing and its potential prognostic value.
Patients and Methods
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were examined. As this was a retrospective analysis of data collected for routine clinical care, individual informed consent was not required (UK National Research Ethics Service guidance).
The study was locally registered and approved.
Data recorded included demographics, information on previous surgical palliations and repairs, details of the surgical procedure including the type of prosthesis used, preoperative New
York Heart Association (NYHA) class, QRS duration from 12 lead surface ECGs and ventricular function assessed by transthoracic echocardiography. Deaths were identified from the hospital database, automatically updated by the Office for National Statistics, which registers all UK deaths.
Preoperative CPEX testing was performed using a symptom-limited graded treadmill exercise. Peak oxygen uptake (peak VO 2 ), ratio of minute ventilation to carbon dioxide production (VE/VCO 2 ) and anaerobic threshold were assessed. Tests were excluded from subsequent analysis if the respiratory quotient value was <1 (n=7). Heart rate reserve was calculated as peak pulse rate on exercise minus resting pulse rate.
The primary outcome measure of the study was all-cause mortality. Early death was defined as death within 30 days of surgery. The secondary outcome measure was need for further pulmonary valve intervention, whether surgical or percutaneous. Follow-up was to the latest clinic visit. To assess the potential impact of surgical era, earlier era was defined as the period between 1993 and 2004 (n=62), whereas later era was the period between 2005 and 2010 (n=159), the latter coinciding with a marked increase in annual surgical volumes of PVR at our centre.
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The pr pr prim im imar ar ary y y ou ou utc tc t om m me e e me me meas as a ur ur ure of of of t t the he he s s stu tu udy dy dy wa wa w s s al al a l-l-l ca ca caus us use e e mo mo mort rt rtal al alit it ty. y. y. E Ear ar a ly ly ly d d dea ea eath t was investigate the association between year of surgery and baseline CPEX parameters. Log-rank statistic was calculated to assess the difference in survival between earlier and later era.
Differences in discrete variables were tested with Chi-squared. Comparison of these features between patients that died and those surviving was also made using unpaired t-tests or Wilcoxon tests depending on data distribution. Kaplan-Meier curves were constructed to illustrate survival and freedom from events and Log rank P-values are provided. The correlation between preoperative parameters of CPEX and early surgical (30 days) mortality was tested using uniand multivariable logistic regression analyses. Cox proportional-hazards analysis was used to assess the association between variables and all-cause mortality. A two-sided P-value <0.05 was considered significant.
Results

Patient characteristics
Patient characteristics are summarised in Table 1 . Between 1993 and 2010, 221 surgical PVRs were performed in 220 adults with rTOF. Median age at PVR was 32 (25 -40) years. Twelve patients (6%) had a previous pulmonary valve implant, including 2 patients who had a conduit type of rTOF. Fifty-six percent of patients were symptomatic with exertional dyspnoea and or fatigue, 21% with clinical arrhythmia, 60% were in New York Heart Association class II, III or IV, 25% were medicated with regular diuretics and 5% has signs or symptoms of heart failure (Table 1) . Four (2%) operations were for acute endocarditis refractory to medical therapy, requiring urgent surgery. An additional 3 (1%) patients had endocarditis which, although medically treated, resulted in valve degeneration requiring subsequent PVR.
Pulmonary valve replacement surgical characteristics
The number of patients undergoing surgical PVR at our centre increased exponentially during considered significant. Table 2 . The length of hospital stay was 7 (6-10) days.
Resu sult lt lts
Mortality
Thirty-day (early) mortality was 2.3%, due to severe RV failure in all 5 cases. Characteristics of patients who died are summarised in Table 3 . Overall survival was 97% at one year (95% confidence interval [CI] 95-99%), 96% at 3 years (95% CI 93-99%) and 92% at 10 years (95% CI 89-97%). Cardiac causes accounted for 8 out of 9 late deaths. Five out of 8 were due to heart failure of which one was in the context of multiorgan failure at 37 days due to unrelenting sepsis despite medical and surgical treatment for the index fulminant infective endocarditis. Three out of 8 late deaths were arrhythmic (witnessed out of hospital cardiac arrests). QRS duration from medical treatment of fungal endocarditis); both underwent surgical percutaneous s p pul ul u mo mo mona na nary ry ry valve explantation combined with surgical PVR. Thirty-six percent of cases involved additional u urg rg rger er ry y y in in incl cl clud ud u in ng g g t tr tricuspid valve repair (13%), br br bran n nch pulmonary y y arter er ry y y au a gmentation (12%)
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Preoperative cardiopulmonary exercise testing as a predictor of mortality
Preoperative cardiopulmonary exercise testing was performed in 154 patients (70% of total, 79% of those operated from 2000 when preoperative CPEX was introduced) at a median of 9 (5-16) months prior to surgery. Preoperative peak VO 2 was significantly lower in those patients that died early; furthermore patients with a lower quartile peak VO 2 had markedly increased mortality ( Figure 2 ).
The median preoperative peak VO 2 was 21.5 mL/kg/min. No patient died with peak VO 2 > 21.5 mL/kg.min. Using a cutoff value of peak VO 2 < 20mL/kg/min, gives 100% sensitivity and 56% specificity for perioperative death. Early mortality for patients with preoperative peak VO 2 < 20mL/kg/min was 5.7% versus 0% in patients with preoperative peak VO 2 20mL/kg/min. Table 4 presents the results of the uni-and multivariate logistic regression analysis exploring the association between peak VO 2 and early mortality. In a stepwise multivariate logistic regression, peak VO 2 achieved was the only independent predictor of early mortality ( Table 4) .
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Outcome
Hospital length of stay was shorter in later era patients compared to earlier era patients (7 [6-9] days versus 9 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] days; P<0.001). Survival following PVR in the earlier era was 94% (95% CI 88-100%) at 1 year, 92% (95% CI 85-99%) at 3 years and 87% (95% CI 79-96%) at 10 years.
Survival in the later era was 99% (95% CI 97-100%) at 1 year and 98% (95%CI 95-100%) at 3 years, which was significantly better when compared with the earlier era (P=0.019) as shown in Freedom from moderate or severe pulmonary stenosis at transthoracic echocardiography was 93% (95% CI 88-98%) at 5 years whereas freedom from moderate or severe pulmonary regurgitation was 95% (95% CI 91-99%) at 5 years (number at risk 48, for both). Of the 5 patients that had pulmonary valve re-intervention after index PVR, 2 underwent further surgical PVR, and 3 percutaneous PVR. All 5 patients had received a homograft (3 aortic, 2 pulmonary) at index PVR. Freedom from redo surgical or transcatheter PVR was 100% at 1 year, 98% at 5 years (95% CI 95-100%), and 96% at 10 years (95% CI 91-100%) ( 
Discussion
In our single centre cohort reflecting 17 years experience of PVR in 220 adults with previous rTOF, pulmonary valve surgery is a low risk endeavour with low early and late mortality.
was 93% (95% CI 88-98%) at 5 years whereas freedom from moderate or severe e pu pu ulm lm mon on onar ar ary y y egurgitation was 95% (95% CI 91-99%) at 5 years (number at risk 48, for both). Of the 5 pa ati ti ien en ents ts ts t t tha ha hat t t h h had d pu pu pulm l onary valve re-interventio o on n n a af fter index PVR, R R 2 u u und nd nder e went further surgical Our data confirm that surgical PVR is a low risk operation. 10, 14, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] This is in spite of the fact that symptomatic patients and patients with multiple previous sternotomies were included in our report. All five patients who died early, however, died from right heart failure suggesting that for significant RV outflow tract obstruction (RV pressure 2/3 systemic) or for sev ev ver r re e pu pu pulm lm lmon on onar ary y egurgitation in conjunction with arrhythmia, exercise intolerance and heart failure. With time, mi mild ld der er r s sym ym mpt pt ptom oms, s s, n new onset TR, or increasing R RV RV size and/or det et ter e io ora ra rat ti ting function became e ele e ect c ive indic icat at tio o ons s. . Wh Wh When en en t the h he de de dele le lete te eri rio ous ef f ffect t ts of p p pu ul ulm m mon na nary ry y r r reg gur ur rgi i ita ati ti ion on w we e ere e e m m more re re f f fu ul u l ly ly ap appr pr prec ec ecia ia i te ted d d ci c circ rca a a 2 20 2000 00 0, as as a ym ym mpt pt ptom om omat at atic ic p p pat at atie ie ien n nts s s wi wi with th p pu u ulmo mo mon na nary ry ry r r reg eg egur ur urgi gi ita ati tion on n w w wer ere e e c c con ns sid d der ere e ed f for o PVR, includi ding ng ng p p pat at atie ie ient nt n s s s wi wi ith th th low ow ower er e o o or de de d cl cl c in in inin in ing g g pe pe peak ak ak V V VO O O 2 , despite our modified, proactive approach for PVR we still operate too late in some cases. Our series, confined to adult patients, had an overall survival of 97% at 1 year, 96 % at 3 years and 92% at 10 years. Therrien et al. reported 92% survival at 5 years and 86% at 10 years in 70 adult rTOF patients after pulmonary valve surgery and early mortality of 4%. 31 Discigil et al. reported 95% survival at 5 years and 76% at 10 years in 42 adults undergoing PVR; the same group reported a 2% early and 14% late mortality amongst children. 26 Our data suggest a drop in mortality in contemporary surgical PVR. This may be associated with higher volume adult congenital heart surgery, improved experience with redo sternotomy, improved surgical myocardial protection and perhaps above all evolving and better selection criteria leading to earlier PVR. Conversely, PVR in the earlier era was performed later in symptomatic patients who may have had a more advanced myocardial impairment accounting for the higher NYHA class and objectively worse impairment of cardiopulmonary exercise capacity. It is reasonable to presume that patients referred for PVR in the earlier era were at a later stage of disease progression. Their reduced peak oxygen uptake 32, 33 or blunted heart rate reserve, 34 and increased VE/VCO 2 slope 35 are all established risk factors for adverse outcome in adult congenital heart disease irrespective of surgery.
Importantly, peak VO 2 was predictive of early mortality in our study. For every mL/min/kg reduction in preoperative peak VO 2 there was an approximately 30% increased risk of early mortality. This novel finding of a relationship between CPEX results and perioperative mortality is of interest and merits further, prospective validation not only in patients undergoing PVR but also in other adult congenital heart disease subjects considered for redo surgery.
Peak VO 2 , was highly sensitive to high operative risk but its limitation is lack of specificity. Though all patients that died had peak VO 2 <20 mL/kg/m 2 , a lower range result for earlier PVR. Conversely, PVR in the earlier era was performed later in symptom ma at atic ic c p p pat at atie ie ient nt nts s s who may have had a more advanced myocardial impairment accounting for the higher NYHA cl las as ss s s an an and d d ob ob obje je ject tiv iv ve el ely y worse impairment of cardio io opu pu ulmonary exer rci ci c se c cap ap apac a ity. It is reasonable to pres s sum u e that p pat at tie ient nts s r refe fe ferr rr rred ed ed f for or P P PVR VR VR i in n th he e earl lie ier r er r ra a we we ere e e a at t a la late ter r st t tag ag ge e e o of of d dis is isea ea ease se e pr prog og ogre re ress ss s io ion n. n. T T The he eir r r red ed duc uc ced ed p pea ea e k k k ox ox oxy yg yge en en u u upt pt ptak k ke e e 32 32 2, 3 33 3 or r r b b blu lu lun n nted ed ed h h hea ea art rt rt r ra a ate e re res se serv rv rve, e, , 34 34 4 a and d d i inc nc n re re eas s sed e VE/VCO 2 slo lope pe pe 35 35 35 a a are re r a a all ll l e est st stab ab abli i ish sh shed ed d ris s sk k k fa fa fact ct c or or ors s fo fo for r ad ad a ve ve vers rs se e e ou ou utc tc tcom om me e e in in in a a adu du dult lt c c con on onge ge geni ni n tal heart peak VO 2 was also recorded in 55% of survivors which in turn did not preclude a good outcome.
Clinically, our data has taught us that a low peak VO 2 may be judiciously used, in conjunction with other clinical data and context, as an indicator of potentially increased surgical risk; patients with peak VO 2 <20 mL/kg/m 2 are more likely therefore to carry a higher surgical risk than the 2% risk reported herewith for allcomers.
Our data show that QRS duration was prolonged in those patients that died. QRS prolongation is a predictor of sustained ventricular tachycardia and sudden cardiac death in rTOF. 3 QRS duration remains a risk factor if prolonged after restoration of pulmonary competence. 36 Mean QRS duration did not shorten significantly 3 years after PVR in our study.
Late cardiac death was arrhythmic in 3 cases despite successful PVR (all 3 patients from the earlier era). This reinforces the point that hemodynamic intervention with PVR alone does not necessarily abort the risk of sudden cardiac death. High risk patients, for example with extensive fibrosis at cardiovascular magnetic resonance imaging, 37, 38 may need and benefit from additional arrhythmia-targeting intervention and/or implantation of an automated internal cardiac defibrillator.
There was an increase in the proportion of xenografts used in the course of our study.
This may reflect limited availability of suitably sized valves and/or a change in surgical preference. A potential advantage of homografts over stented valves (xenografts) is better hemodynamics. Homografts may also provide a more suitable substrate for later percutaneous pulmonary valve implantation. A perceived disadvantage of homografts is the greater risk for early regurgitation if the geometry of the valve is jeopardized during implantation. This may be true when a markedly enlarged and distorted right ventricular outflow tract is present. In the current study, there was no differences in the durability of homografts compared to xenografts.
Late cardiac death was arrhythmic in 3 cases despite successful PVR (all 3 patie en n nts s f from om om t t the he he earlier era). This reinforces the point that hemodynamic intervention with PVR alone does not ne ece ce cess ss sa ar aril il ily y y ab ab abor rt t t th th the e risk of sudden cardiac deat th h. h. H H High risk patie ent n n s, f f for or or e example with extensive fi fi ibr r ros o is at card dio io iova a asc cu ul u ar ar ar m m mag ag agn ne neti ti ic c c r re res so on n nanc c ce ima ag agi ing, g, g, r r 37, 37 7, 38 38 8 m m may ay n nee eed d d a an and d be be ben ne nefi fit t t fr from om om a a add d ddit it itio o ona ar rrh rh rhyt yt ythm hm h ia ia a-t -t -ta ar arge ge eti tin ng ng i i int nter erve vent nt n io io on n n an an and/ d/or or or i i imp mp mpl lan an anta ta ati ion on of f f an an an a a aut ut u o om omat at ated ed ed in nt nter er rna na nal l l ca ca ard rd rdi iac c c defibrillator. . Longer follow-up data may be necessary to elucidate the potential advantages of the superior hemodynamics associated with homografts. There was no difference in early mortality associated with choice of prosthesis.
Clearly, additional markers to current indices are required for optimal timing of PVR.
CPEX testing may be one of them. Surgical PVR may be lower risk when cardiovascular fitness is maintained, justifying earlier intervention. Indeed, our data show that a better peak VO 2 at baseline is associated with lower early mortality after PVR. Patients who had follow-up CPEX seem to have stable rather than improving exercise capacity in the medium term. This may be a reflection that isolated pulmonary regurgitation was the most common culprit lesion for PVR in our series. Others have demonstrated similar lack of improvement in peak VO 2 following PVR unless pulmonary stenosis was the predominant lesion preoperatively. 14, 39, 40 Heart rate reserve and VE/VCO 2 slope also remained unchanged in our study. Thus far, RV volumes do not correlate well with peak VO 2 in pulmonary regurgitation. 41, 42 Despite improvement in LV filling and cardiac output and reduction in RV volumes after PVR 14, 28, 43 peak VO 2 has not been found to improve post intervention in our study or in other studies. 14, 39, 14, 40 Pulmonary regurgitation may significantly limit cardiac output during exercise although other factors such as reduced diastolic time with increased heart rate, abnormal RV diastolic and pressure response to exercise due to myocardial fibrosis and or hypertrophy, and reduced pulmonary vascular resistance may also play a role in effective forward pulmonary blood flow. For these reasons, peak VO 2 may be insensitive to change following restoration of pulmonary valve competence. Additionally, once peak VO 2 becomes impaired irreversible RV dysfunction may already play a role. It may be that different responses to surgery are due to differing degrees of RV stiffness and fibrosis. Fibrosis may be due to factors present before repair such as cyanosis and pressure overload or as a result our series. Others have demonstrated similar lack of improvement in peak VO 2 fo fo oll low ow o in in ng g g PV PV PVR R unless pulmonary stenosis was the predominant lesion preoperatively. 14, 39, 40 Heart rate reserve an nd d d VE VE VE/V /V /VCO CO CO 2 s slo lo lop pe pe also remained unchanged in n n ou u ur study. Thus s fa f r, , R R RV V V volumes do not co orr r rel e ate well w wit i i h h h pe peak ak k V V VO O O 2 2 i i in n pu pu ulm lm lmo on ona ary re reg gurg g gi it tatio io on n n. 41 postoperatively is anticipated. Given the poor correlation between peak VO 2 and RV volume increase due to pulmonary regurgitation 41, 42 such cutoff values in a future larger study may or may not relate to those so far suggested for RV recovery as measured by reduction in RV
volumes measured with cardiovascular magnetic resonance (CMR). We propose therefore, that PVR may still be considered too late even with our current proactive approach to generate significant improvement in exercise capacity. Earlier intervention, in the presence of a more compliant RV with preserved RV function, may lead to improved exercise performance but this clearly needs to be validated in future studies. Peak VO 2 is a composite measure of integrated cardiovascular and respiratory function and may also reflect physical conditioning and other comorbidity. Not all these aspects will necessarily be improved with hemodynamic intervention alone but, nevertheless contribute to surgical risk.
Freedom from surgical or transcatheter pulmonary valve reimplantation in our adult series was reassuring at 100% at 1 year, 98% at 5 years and 96% at 10 years. Freedom from redo homograft replacement was 91% at 5 years and 84% at 10 years in the Oosterhof et al., study of 116 rTOF patients, 17 and freedom from redo PVR 75% at 10 years in the study of 170 adults and children by Lee et al., 16 suggesting an improving trend of lesser need for re-intervention in our series.
While we advocate earlier PVR, this approach may not be without potential problems.
Younger age at pulmonary valve replacement may be associated with a higher rate of valve failure and early reoperation 44, 45 though this should be less of an issue in adult patients where compliant RV with preserved RV function, may lead to improved exercise perfo orm rm rman a a ce ce c b b but ut ut t th his clearly needs to be validated in future studies. Peak VO d 2 is a composite measure of integrated ca ard rd dio io iov va vasc sc cul ul ula a ar a and nd nd r respiratory function and may y y a als so reflect physi si ica c l co co con n nditioning and other com mor rb rbidity. Not ot a a all the hes se a asp sp spec ec ect ts ts w w wil il i l l l n ne ec cessa a ari i ily b b be im mpr pr prov oved ed ed w wi it th h he hem mo mody dyna na nam mi mic c in in inte te t rv rv ven en enti tio on on al lon on one e e bu bu b t, t, , n n nev e ever ert th the el eles ess s c co cont n ri ri ribu bu ute te te t t to o o su su urg rg gic ic ica a al r r ris is isk. k. .
Freedo do om m m fr fr from om om s sur u u gi gi gica ca cal or or or t tra ra ans nsca ca c th th thet et eter er er p p pul ul u mo mo mona a ary ry ry v v val al a ve ve ve r rei i imp mp mpla la lan n nta ta ati tion on on i i in n n ou ou our r adult somatic growth is not a concern. Operating earlier on the assumption that next valve implantation can be performed percutaneously carries an additional appeal but some patients may not be suitable for this evolving technique in future. Hence, longevity of pulmonary valve prostheses remains a concern with respect to timing of surgical pulmonary valve implantation.
Limitations
Our data are limited by the retrospective study design. Although 70% of patients had preoperative CPEX testing, paired pre-and post-operative CPEX data were only available in 24% (53 patients). Though there was clear value in preoperative peak VO 2 in evaluating mortality risk, low peak VO 2 was highly sensitive but not specific and causality cannot be assumed. Furthermore, the indications for PVR evolved with time during the study period and were individualised to patients rather than adhered to a protocol. Nevertheless, we report the largest (n=221), single centre, unselected clinical series with a complete data set on early and late mortality and on the need for re-intervention.
Outcomes from our tertiary centre with high volume care of congenital heart disease cannot necessarily be extrapolated to other settings. We believe, however, our group of patients to be representative of contemporary tertiary practice.
Imaging data with CMR derived ventricular volumes were not routinely acquired for all patients. This is because of the relatively long period of observation without exclusions dating back to 1993 and the lack of defined CMR cut-offs for pulmonary regurgitation at the time to guide surgery. were individualised to patients rather than adhered to a protocol. Nevertheless, we report the a arg rg ges es est t t ( (n (n=2 =2 =221 2 2 ), s s sin in ingl g e centre, unselected clinica a al l l se e eries with a co omp m m le ete te te d data set on early and late m mor rt rtality and on on th he he n n nee ee ed d d fo fo for r r r re re-i -in nt nte er erv ven n ntion n n.
Ou Outc tc tco om ome es f f fro rom m m ou ou o r r te te ert rtia ia iary ry ry c cen en ntr r re e e w w with h h h hi i igh gh h v vol ol o um um ume e ca ca care re e o o of f f co co cong ng nge eni ni ita ta tal l l he he ear ar art t di di ise e eas ase e e cannot neces ssa sa sari ri r ly ly ly b b be e ex ex extrap ap apol ol o at at ted ed ed t t to o o ot ot othe he her r r se se sett tt t in in i gs gs gs. . We We We b b bel el elie ie ieve ve ve, , ho ho owe we weve ve ver, r, r, o o our ur r g g gro ro roup up up o of patients degree of postoperative RV volume change, however, are the subject of ongoing prospective studies.
Conclusions
Pulmonary valve replacement has a low and improving mortality, with low 10-year reintervention rates. Patients operated more recently in our cohort were less symptomatic and had better exercise capacity at the time of referral for surgical PVR compared to those operated in the earlier part of the study, reflecting recent trends towards earlier PVR. This trend of earlier PVR was associated with lower mortality. Furthermore, preoperative peak oxygen uptake was predictive of early postoperative mortality, reinforcing the value of CPEX in this patient group. 
